22-05-2025
ASCO 2025: Previewing Updates in Early-Stage Breast Cancer
Mariana Chavez MacGregor, MD, MSc, shares her enthusiasm for the 2025 ASCO Annual Meeting, particularly for its relevance to early-stage breast cancer. She highlights key sessions focused on treatment optimization and de-escalation for HER2-positive patients, along with important updates on the management of HR-positive breast cancer in premenopausal women, including the SOFT, TEXT, and ASTRRA trials.
Dr Chavez MacGregor also points to new research on elinzanetant for managing vasomotor symptoms associated with endocrine therapy. Additionally, she is eager to attend the Dr Bernard Fisher Memorial Annual Clinical Science Symposium, which will explore circulating tumor DNA and its role in monitoring early-stage breast cancer.
